Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2020

01-09-2020 | Metastasis | Colorectal Cancer

Extent of Peritoneal Metastases on Preoperative DW-MRI is Predictive of Disease-Free and Overall Survival for CRS/HIPEC Candidates with Colorectal Cancer

Authors: Maurits P. Engbersen, MSc, Arend G. J. Aalbers, MD, Iris Van‘t Sant-Jansen, MD, Jeroen D. R. Velsing, MD, Doenja M. J. Lambregts, MD, PhD, Regina G. H. Beets-Tan, MD, PhD, Niels F. M. Kok, MD, PhD, Max J. Lahaye, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2020

Login to get access

Abstract

Objective

The aim of this study was to determine whether the extent of peritoneal metastases (PMs) on preoperative diffusion-weighted magnetic resonance imaging (DW-MRI) can be used as a biomarker of disease-free and overall survival in patients with colorectal cancer who are considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Methods

For this retrospective cohort study, patients with PMs considered for CRS/HIPEC who underwent DW-MRI for preoperative staging in 2016–2017 were included. The DW-MRI protocol consisted of diffusion-weighted, T2-weighted, and pre- and post-gadolinium T1-weighted imaging of the chest, abdomen, and pelvis. DW-MRI images were evaluated by two independent readers to determine the extent of PMs represented by the Peritoneal Cancer Index (MRI-PCI), as well as extraperitoneal metastases. Cox regression and Kaplan–Meier analysis was performed to determine the prognostic value of DW-MRI for overall and disease-free survival.

Results

Seventy-eight patients were included. CRS/HIPEC was planned for 53 patients and completed in 50 patients (60.5%). Median follow-up after DW-MRI was 23 months (interquartile range 13–24). The MRI-PCI of both readers showed prognostic value for overall survival, independently of whether R1 resection was achieved (hazard ratio [HR] 1.06–1.08; p < 0.05). For the patients who received successful CRS/HIPEC, the MRI-PCI also showed independent prognostic value for disease-free survival for both readers (HR 1.09–1.10; p < 0.05).

Conclusion

The extent of PMs on preoperative DW-MRI is an independent predictor of overall and disease-free survival and should therefore be considered as a non-invasive prognostic biomarker.
Literature
1.
Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–1550.PubMedCrossRef
2.
Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699–705.PubMedCrossRef
3.
van Gestel YR, Thomassen I, Lemmens VE, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40(8):963–969.PubMedCrossRef
4.
Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257(6):1065–1071.PubMedCrossRef
5.
Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(18 Suppl):3503.CrossRef
6.
Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63–68.PubMedCrossRef
7.
Verwaal VJ, Van Ruth S, De Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–3743.PubMedCrossRef
8.
da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878–886.PubMedCrossRef
9.
van Oudheusden TR, Braam HJ, Luyer MD, et al. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis. Ann Surg Oncol. 2015;22(4):1236–1242.PubMedCrossRef
10.
Dohan A, Hobeika C, Najah NH, Pocard M, Rousset P, Eveno C. Preoperative assessment of peritoneal carcinomatosis of colorectal origin. J visc Surg. 2018;155(4):293–303.PubMedCrossRef
11.
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374.PubMedCrossRef
12.
de Bree E, Koops W, Kroger R, van Ruth S, Verwaal VJ, Zoetmulder FA. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2006;32(1):65–71.PubMedCrossRef
13.
de Bree E, Koops W, Kroger R, van Ruth S, Witkamp AJ, Zoetmulder FA. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86(2):64–73.PubMedCrossRef
14.
Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327–333.PubMedCrossRef
15.
Koh FHX, Tan KK, Teo LLS, Ang BWL, Thian YL. Prospective comparison between magnetic resonance imaging and computed tomography in colorectal cancer staging. ANZ J Surg. 2018;88(6):E498–E502.PubMedCrossRef
16.
Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565–570.PubMedCrossRef
17.
Taylor S, Mallett S, Beare S, et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. Lancet Gastroenterol Hepatol. 2019;4(7):529–537.PubMedPubMedCentralCrossRef
18.
Lambregts DM, Maas M, Cappendijk VC, et al. Whole-body diffusion-weighted magnetic resonance imaging: current evidence in oncology and potential role in colorectal cancer staging. Eur J Cancer. 2011;47(14):2107–2116.PubMedCrossRef
19.
Low RN, Barone RM. Imaging for Peritoneal Metastases. Surgical oncology clinics of North America. 2018;27(3):425-442.PubMedCrossRef
20.
Barral M, Eveno C, Hoeffel C, et al. Diffusion-weighted magnetic resonance imaging in colorectal cancer. J Visc Surg. 2016;153(5):361–369.PubMedCrossRef
21.
Zhang H, Dai W, Fu C, et al. Diagnostic value of whole-body MRI with diffusion-weighted sequence for detection of peritoneal metastases in colorectal malignancy. Cancer Biol Med. 2018;15(2):165–170.PubMedPubMedCentralCrossRef
22.
van ‘t Sant I, van Eden WJ, Engbersen MP, et al. Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. Br J Surg. 2019;106(4):491-498.CrossRef
23.
Dresen RC, De Vuysere S, De Keyzer F, et al. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases. Cancer Imaging. 2019;19(1):1.PubMedPubMedCentralCrossRef
24.
Burnett A, Lecompte MA, Trabulsi N, et al. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. World J Surg Oncol. 2019;17(1):83.PubMedPubMedCentralCrossRef
25.
Clark TG, Altman DG, Stavola BLD. Quantification of the completeness of follow-up. Lancet. 2002;359(9314):1309–1310.PubMedCrossRef
26.
Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and cox regression. Am J Epidemiol. 2006;165(6):710–718.PubMedCrossRef
27.
Goéré D, Souadka A, Faron M, et al. Extent of Colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22(9):2958–2964.PubMedCrossRef
28.
Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark KJ. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. JOSO. 2016;114(2):222–227.
29.
Braam HJ, Van Oudheusden TR, De Hingh IH, et al. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. J Surg Oncol. 2014;109(8):841–847.PubMedCrossRef
30.
Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012;19(5):1394–1401.PubMedCrossRef
31.
Engbersen MP, Sant I, Lok C, et al. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. Eur J Radiol. 2019;114:146–151.PubMedCrossRef
32.
Klumpp BD, Aschoff P, Schwenzer N, et al. Correlation of preoperative magnetic resonance imaging of peritoneal carcinomatosis and clinical outcome after peritonectomy and HIPEC after 3 years of follow-up: preliminary results. Cancer Imaging. 2013;13(4):540–7.PubMedCrossRef
33.
Iversen LH, Rasmussen PC, Laurberg SJ. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg. 2013;100(2):285–292.PubMedCrossRef
34.
Tabrizian P, Jayakrishnan TT, Zacharias A, et al. Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: a multi-institutional analysis. J Surg Oncol. 2015;111(8):1035–1040.PubMedCrossRef
Metadata
Title
Extent of Peritoneal Metastases on Preoperative DW-MRI is Predictive of Disease-Free and Overall Survival for CRS/HIPEC Candidates with Colorectal Cancer
Authors
Maurits P. Engbersen, MSc
Arend G. J. Aalbers, MD
Iris Van‘t Sant-Jansen, MD
Jeroen D. R. Velsing, MD
Doenja M. J. Lambregts, MD, PhD
Regina G. H. Beets-Tan, MD, PhD
Niels F. M. Kok, MD, PhD
Max J. Lahaye, MD, PhD
Publication date
01-09-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08416-7

Other articles of this Issue 9/2020

Annals of Surgical Oncology 9/2020 Go to the issue

Gastrointestinal Oncology

The Landmark Series: Neuroendocrine Tumor Liver Metastases

Gastrointestinal Oncology

Salvage Esophagectomy for Residual Tumor After Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Invading the Neighboring Organs: Is it a Feasible Choice?

Translational Research and Biomarkers

Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases

ASO Author Reflections

ASO Author Reflections: Developing Personalized Care for Hepatocellular Adenoma Based on Subtype Classification

ASO Author Reflections

ASO Author Reflections: Assessing the Outcomes of Liver Cancer Patients Undergoing Surgery Over the Last Decade—Are We Doing Better?

Breast Oncology

The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer